5-azacytidine treatment reorganizes genomic histone modification patterns

Vitalina M. Komashko, Peggy J. Farnham

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Methylation of DNA in combination with histone modifications establishes an epigenetic code that ensures the proper control of gene expression. Although DNA methyltransferases have been shown to interact with histone methyltransferases such as EZh2 (which methylates histone h3 on lysine 27) and G9a (which methylates histone h3 on lysine 9), the relationship between DNA methylation and repressive histone marks has not been fully studied. In cancer cells, promoters of genes are often aberrantly methylated. Accordingly, 5-azacytidine (a DNA demethylating drug) is used for treating patients with myelodysplastic syndrome. however, no genome-scale studies of the effects of this drug have been reported. In this work, we report the effects of 5-azacytidine on global gene expression and analyze ∼24,000 human promoters using chIp-chip to determine how 5-azacytidine treatment effects h3K27me3 and h3K9me3 levels. We found that (1) 5-azacytidine treatment results in large changes in gene regulation with distinct functional categories of genes showing increased (e.g., c2h2 zinc finger transcription factors) and decreased (e.g., genes involved in regulation of mitochondria and oxidoreductase activity) levels, (2) most genes that show altered expression are not regulated by promoters that display DNA methylation prior to the treatment, (3) certain gene classes switch their repression mark upon treatment with 5-azacytidine (from h3K27me3 to h3K9me3 and vice versa), and (4) most changes in gene expression are not due to relief of repression mediated by DNA or histone methylation.

Original languageEnglish (US)
Pages (from-to)229-240
Number of pages12
JournalEpigenetics
Volume5
Issue number3
DOIs
StatePublished - 2010

Fingerprint

Histone Code
Azacitidine
DNA Methylation
Histones
Genes
Gene Expression
Lysine
DNA
Switch Genes
Therapeutics
Myelodysplastic Syndromes
Methyltransferases
Epigenomics
Pharmaceutical Preparations
Methylation
Mitochondria
Oxidoreductases
Transcription Factors
Genome
Neoplasms

Keywords

  • 5-azacytidine
  • Cancer cells
  • ChIP-chip
  • DNA methylation
  • H3K27me3
  • H3K9me3
  • Transcriptional repression

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Medicine(all)

Cite this

5-azacytidine treatment reorganizes genomic histone modification patterns. / Komashko, Vitalina M.; Farnham, Peggy J.

In: Epigenetics, Vol. 5, No. 3, 2010, p. 229-240.

Research output: Contribution to journalArticle

Komashko, Vitalina M. ; Farnham, Peggy J. / 5-azacytidine treatment reorganizes genomic histone modification patterns. In: Epigenetics. 2010 ; Vol. 5, No. 3. pp. 229-240.
@article{ab49cb16d43d4b0a829c9b9237643146,
title = "5-azacytidine treatment reorganizes genomic histone modification patterns",
abstract = "Methylation of DNA in combination with histone modifications establishes an epigenetic code that ensures the proper control of gene expression. Although DNA methyltransferases have been shown to interact with histone methyltransferases such as EZh2 (which methylates histone h3 on lysine 27) and G9a (which methylates histone h3 on lysine 9), the relationship between DNA methylation and repressive histone marks has not been fully studied. In cancer cells, promoters of genes are often aberrantly methylated. Accordingly, 5-azacytidine (a DNA demethylating drug) is used for treating patients with myelodysplastic syndrome. however, no genome-scale studies of the effects of this drug have been reported. In this work, we report the effects of 5-azacytidine on global gene expression and analyze ∼24,000 human promoters using chIp-chip to determine how 5-azacytidine treatment effects h3K27me3 and h3K9me3 levels. We found that (1) 5-azacytidine treatment results in large changes in gene regulation with distinct functional categories of genes showing increased (e.g., c2h2 zinc finger transcription factors) and decreased (e.g., genes involved in regulation of mitochondria and oxidoreductase activity) levels, (2) most genes that show altered expression are not regulated by promoters that display DNA methylation prior to the treatment, (3) certain gene classes switch their repression mark upon treatment with 5-azacytidine (from h3K27me3 to h3K9me3 and vice versa), and (4) most changes in gene expression are not due to relief of repression mediated by DNA or histone methylation.",
keywords = "5-azacytidine, Cancer cells, ChIP-chip, DNA methylation, H3K27me3, H3K9me3, Transcriptional repression",
author = "Komashko, {Vitalina M.} and Farnham, {Peggy J.}",
year = "2010",
doi = "10.4161/epi.5.3.11409",
language = "English (US)",
volume = "5",
pages = "229--240",
journal = "Epigenetics",
issn = "1559-2294",
publisher = "Landes Bioscience",
number = "3",

}

TY - JOUR

T1 - 5-azacytidine treatment reorganizes genomic histone modification patterns

AU - Komashko, Vitalina M.

AU - Farnham, Peggy J.

PY - 2010

Y1 - 2010

N2 - Methylation of DNA in combination with histone modifications establishes an epigenetic code that ensures the proper control of gene expression. Although DNA methyltransferases have been shown to interact with histone methyltransferases such as EZh2 (which methylates histone h3 on lysine 27) and G9a (which methylates histone h3 on lysine 9), the relationship between DNA methylation and repressive histone marks has not been fully studied. In cancer cells, promoters of genes are often aberrantly methylated. Accordingly, 5-azacytidine (a DNA demethylating drug) is used for treating patients with myelodysplastic syndrome. however, no genome-scale studies of the effects of this drug have been reported. In this work, we report the effects of 5-azacytidine on global gene expression and analyze ∼24,000 human promoters using chIp-chip to determine how 5-azacytidine treatment effects h3K27me3 and h3K9me3 levels. We found that (1) 5-azacytidine treatment results in large changes in gene regulation with distinct functional categories of genes showing increased (e.g., c2h2 zinc finger transcription factors) and decreased (e.g., genes involved in regulation of mitochondria and oxidoreductase activity) levels, (2) most genes that show altered expression are not regulated by promoters that display DNA methylation prior to the treatment, (3) certain gene classes switch their repression mark upon treatment with 5-azacytidine (from h3K27me3 to h3K9me3 and vice versa), and (4) most changes in gene expression are not due to relief of repression mediated by DNA or histone methylation.

AB - Methylation of DNA in combination with histone modifications establishes an epigenetic code that ensures the proper control of gene expression. Although DNA methyltransferases have been shown to interact with histone methyltransferases such as EZh2 (which methylates histone h3 on lysine 27) and G9a (which methylates histone h3 on lysine 9), the relationship between DNA methylation and repressive histone marks has not been fully studied. In cancer cells, promoters of genes are often aberrantly methylated. Accordingly, 5-azacytidine (a DNA demethylating drug) is used for treating patients with myelodysplastic syndrome. however, no genome-scale studies of the effects of this drug have been reported. In this work, we report the effects of 5-azacytidine on global gene expression and analyze ∼24,000 human promoters using chIp-chip to determine how 5-azacytidine treatment effects h3K27me3 and h3K9me3 levels. We found that (1) 5-azacytidine treatment results in large changes in gene regulation with distinct functional categories of genes showing increased (e.g., c2h2 zinc finger transcription factors) and decreased (e.g., genes involved in regulation of mitochondria and oxidoreductase activity) levels, (2) most genes that show altered expression are not regulated by promoters that display DNA methylation prior to the treatment, (3) certain gene classes switch their repression mark upon treatment with 5-azacytidine (from h3K27me3 to h3K9me3 and vice versa), and (4) most changes in gene expression are not due to relief of repression mediated by DNA or histone methylation.

KW - 5-azacytidine

KW - Cancer cells

KW - ChIP-chip

KW - DNA methylation

KW - H3K27me3

KW - H3K9me3

KW - Transcriptional repression

UR - http://www.scopus.com/inward/record.url?scp=77954688477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954688477&partnerID=8YFLogxK

U2 - 10.4161/epi.5.3.11409

DO - 10.4161/epi.5.3.11409

M3 - Article

VL - 5

SP - 229

EP - 240

JO - Epigenetics

JF - Epigenetics

SN - 1559-2294

IS - 3

ER -